ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future
- On Monday, July 13, 2026, the U.S. Food and Drug Administration approved a supplemental Biologics License Application for Eisai Co., Ltd. and Biogen Inc.'s LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease initiation dosing.
- Previously, patients received the medication through intravenous infusions, typically administered at clinics. This new subcutaneous formulation allows patients or caregivers to self-administer the treatment via an autoinjector, reducing clinic visit burdens.
- Clinical data showed subcutaneous administration achieved exposure equivalent to intravenous dosing, supporting similar efficacy and biomarker benefits. An autoinjector acceptability study indicated 94% of patients and care partners found the device easy to use.
- The treatment is expected to be available in the U.S. in late August 2026, differentiating LEQEMBI IQLIK from competitor Eli Lilly's Kisunla, which requires intravenous infusions and potentially increasing patient uptake.
- Howard Fillit, Co-Founder and Chief Science Officer Emeritus of the Alzheimer's Drug Discovery Foundation , said the approval "marks a new era of Alzheimer's treatments," with innovations supporting precision medicine and potential combination therapies.
48 Articles
48 Articles
MedPage Today
NewsmaxFDA Approves At-Home Starter Dose of Alzheimer's Drug
(MedPage Today) -- The FDA approved a new starting dosage regimen for the subcutaneous formulation of lecanemab (Leqembi Iqlik) to treat adults with Alzheimer's disease, the agency said Monday. Lecanemab is an anti-amyloid monoclonal antibody...
Rockdale Citizen & Newton Citizen
ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future
Initiation of treatment with subcutaneous administration opens the door to fully at-home dosing, similar to injectable diabetes and GLP-1 weight loss therapies
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK...
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
/PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental...
Coverage Details
Bias Distribution
- 76% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
